Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Biomarker and AI-supported FX06 therapy to prevent progression from mild and moderate to severe stages of COVID-19

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Overview of policy landscape (si apre in una nuova finestra)

This report describes current policies at the European and if useful national levels that guide or determine the development of new drugs against COVID19

Report on collaborations and impact assessment (si apre in una nuova finestra)

This reports describes the first activities with other research and innovation initiatives and established contacts as well as an impact assessment of these An updated version will be submitted at the end of the projectA brief report on the main outcomes of the meeting with the European COVID19 clinical trial network for therapeutics covid19trialseu and possible followup actions will be considered Upon availability of clinical trial data that would allow further evaluation in Phase II clinical trials of the developed therapeutic compounds the coordinator will contact the European COVID19 clinical trial network for therapeutics covid19trialseuecrinorg to explore the compounds suitability for the European network of largescale multicentre clinical trials for hospitalized patients covid19trialseu

"Report on virtual meeting with the other successful projects working on COVID-19 therapeutics funded under the Horizon Europe call ""HORIZON-HLTH-2021-CORONA-01" (si apre in una nuova finestra)

A virtual meeting will be set up by DG RTD in coordination with HaDEA between the projects working on COVID19 therapeutics funded under the Horizon Europe call HORIZONHLTH2021CORONA01 at the beginning of the projects lifetime This meeting is to introduce each project to each other and to identify areas for potential collaboration The brief report submitted shall include the minutes of the meeting and a plan on how to move forward in identified possible areas of collaboration Participation of the coordinators of the European COVID19 clinical trial network for therapeutics covid19trialseu will be considered for this meeting to introduce the relevant adaptive platform trials

Analysis of barriers for uptake (si apre in una nuova finestra)

This report describes possible barriers related to the future update of the FX06based therapy by clinical staff and other stakeholder groups

Interim impact report (si apre in una nuova finestra)

This report describes the results of an assessment of the communication and dissemination measures impact

Governance Report (si apre in una nuova finestra)

This report describes the organisational structure of the project management the roles and responbilities of the consortium bodies as defined in the Consortium Agreement

Training material (si apre in una nuova finestra)

This report describes the types structure and content of training material to be used for the training of clinical staff before and during the implementation of the clinical study

"Progress report on the collaborative actions between the projects working on COVID-19 therapeutics funded under the Horizon Europe call ""HORIZON-HLTH-2021-CORONA-01""" (si apre in una nuova finestra)

The brief report will provide an update on the collaborative efforts that were undertaken in the first 18 months of the pro-jects’ duration, also according to what was laid in D1.7.

Plan for dissemination including communication activities (si apre in una nuova finestra)

This report describes the aims the strategy and the planned measures related to the communication and dissemination of the project and its results

COVend website (si apre in una nuova finestra)

The project website documentation covers technical aspects the first website structure and initial content

Pubblicazioni

Additional file 1 of Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled IXION study (si apre in una nuova finestra)

Autori: Kloka, Jan; Friedrichson, Benjamin; Dauth, Stephanie; Foldenauer, Ann Christina; Bulczak-Schadendorf, Anita; Vehreschild, Maria J. G. T.; Matos, Francisco Maio; Riera-Mestre, Antoni; van Asselt, Antoinette D. I.; De Robertis, Edoardo; Juskeviciene, Vilma Traskaite; Meybohm, Patrick; Tomescu, Dana; Lacombe, Karine; Stehouwer, Coen D. A.; Zacharowski, Kai
Pubblicato in: 2022, ISSN 0967-0912
Editore: Institute of Materials
DOI: 10.6084/m9.figshare.20521689

Microvascular Leakage as Therapeutic Target for Ischemia and Reperfusion Injury (si apre in una nuova finestra)

Autori: Jan Andreas Kloka; Benjamin Friedrichson; Petra Wülfroth; Rainer Henning; Kai Zacharowski
Pubblicato in: Cells, Vol 12, Iss 10, p 1345 (2023), 2023, ISSN 2073-4409
Editore: MDPI
DOI: 10.3390/cells12101345

PharmacoEconomics (si apre in una nuova finestra)

Autori: Clazinus Veijer; Marinus H. van Hulst; Benjamin Friedrichson; Maarten J. Postma; Antoinette D.I. van Asselt
Pubblicato in: PharmacoEconomics, 2024, ISSN 1170-7690
Editore: Adis International Ltd
DOI: 10.1007/S40273-024-01375-X

Artificial intelligence research in the COVend COVID-19 clinical trial project (si apre in una nuova finestra)

Autori: Värri, A. O., Kallonen, A., Asuroglu, T., & van Gils, M.
Pubblicato in: Finnish Journal of eHealth and eWelfare, 2023, ISSN 1798-0798
Editore: Finnish Social and Health Informatics Association
DOI: 10.23996/fjhw.126881

Potential of FX06 to prevent disease progression in hospitalized non‑intubated COVID‑19 patients — the randomized, EU‑wide, placebo‑controlled IXION study (si apre in una nuova finestra)

Autori: Kloka, Jan; Friedrichson, Benjamin; Dauth, Stephanie; Foldenauer, Ann Christina; Bulczak Schadendorf, Anita; Vehreschild, Maria J. G. T.; Matos, Francisco Maio; Riera Mestre, Antoni; Van Asselt, Antoinette D. I.; De Robertis, Edoardo; Juskeviciene, Vilma
Pubblicato in: Trials, 23(1):688. BioMed Central Ltd, 2022, ISSN 1745-6215
Editore: Trials
DOI: 10.1186/s13063-022-06609-x

È in corso la ricerca di dati su OpenAIRE...

Si è verificato un errore durante la ricerca dei dati su OpenAIRE

Nessun risultato disponibile

Il mio fascicolo 0 0